Welcome to our dedicated page for Pacira BioSciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira BioSciences stock.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is a pioneering company dedicated to advancing non-opioid pain management and regenerative health solutions. Headquartered in Tampa, Florida, Pacira is committed to providing innovative treatments that minimize the reliance on opioids for pain relief, thereby redefining the role of opioids as a rescue therapy only.
Pacira has three primary commercialized products: EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), and ioveraº®. EXPAREL, launched in 2012, is a long-acting local analgesic used for postsurgical pain management, offering significant reductions in opioid consumption and cumulative pain scores. ZILRETTA, approved in 2017, is an extended-release intra-articular injection aimed at managing osteoarthritis knee pain, providing extended pain relief without repeated administration. ioveraº is a novel handheld device that delivers precise, controlled doses of cold temperature to targeted nerves, offering immediate, drug-free pain relief.
The company’s advanced DepoFoam® delivery platform encapsulates drugs in a multivesicular liposome, releasing them over extended periods without altering their molecular structure. This technology underpins the efficacy of Pacira’s flagship product, EXPAREL, which has been pivotal in reducing opioid use and enhancing postoperative recovery.
Pacira continues to innovate with ongoing clinical developments and strategic initiatives. Recently, the company reported preliminary unaudited total revenue of $675.0 million for the fiscal year 2023. In 2024, Pacira plans to launch EXPAREL for two key lower extremity nerve blocks and anticipates the rollout of the NOPAIN Act in 2025, which will expand patient access to opioid-sparing pain management solutions.
Pacira’s commitment to developing non-opioid treatments is further demonstrated by its recent achievements in securing FDA and European Medicines Agency designations for PCRX-201, a gene therapy product candidate for osteoarthritis. The company’s focus on long-term growth and operational excellence remains steadfast under the leadership of CEO Frank D. Lee.
For more information on Pacira BioSciences and its product offerings, visit www.pacira.com.
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced that the FDA has approved EXPAREL for use in children aged 6 and older, making it the first long-acting local analgesic for this age group. This approval expands EXPAREL's indication for single-dose infiltration for postsurgical pain management, addressing a critical need for non-opioid alternatives in pediatric care. The approval is based on positive data from the Phase 3 PLAY study, which involved 98 pediatric patients. The company aims to reduce opioid exposure among children undergoing surgery.
Pacira BioSciences, Inc. (Nasdaq: PCRX) reported preliminary unaudited net product sales of EXPAREL at $35.6 million for February 2021, with average daily sales at 103% compared to last year. Despite ongoing COVID-19 challenges, the company observed strong demand for non-opioid pain management solutions, especially in outpatient settings. The impact of the pandemic continues to affect elective surgeries, but Pacira remains focused on leveraging EXPAREL and iovera° to enhance market presence. The company plans to report monthly sales data to provide transparency.
PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX) will present at the 2021 Barclays Global Healthcare Conference on March 9, 2021, at 10:55 AM ET. Interested parties can access the live audio from the company’s website's Events page, with a replay available for two weeks post-event. Pacira leads in non-opioid pain management solutions, notably with its long-acting local analgesic, EXPAREL®, launched in April 2012. The company aims to reduce opioid reliance, further emphasized by its acquisition of the iovera°® cryoanalgesia device in April 2019.
Pacira BioSciences (PCRX) reported record full-year 2020 revenue of $429.6 million, a 2% increase from 2019. The fourth quarter revenue reached $131.0 million, up 7% year-over-year. GAAP net income for the year was $145.5 million, or $3.41 per share. Despite challenges from the COVID-19 pandemic, EXPAREL sales drove strong growth, reaching $413.3 million. The European Commission approved EXPAREL for post-surgical pain, expanding market opportunities. Pacira remains committed to opioid alternatives amid the ongoing opioid crisis.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will report its fourth quarter and full year 2020 financial results on February 25, 2021, before U.S. market opening. A live conference call and webcast will follow at 8:30 a.m. ET, with participation accessible via a dedicated phone line and on their website. Pacira is committed to non-opioid pain management, focusing on its long-acting local analgesic, EXPAREL®, launched in 2012, and the iovera°® cryoanalgesia device acquired in 2019.
Pacira BioSciences reported preliminary unaudited net product sales of EXPAREL and iovera° totaling $34.9 million and $1.1 million, respectively, for January 2021. Average daily sales for EXPAREL reached 108% of the prior year, signaling ongoing growth despite COVID-19 challenges. The company emphasizes the successful adoption of EXPAREL in elective surgeries and its relevance in expedited recovery protocols. However, COVID-19 continues to negatively impact elective surgical schedules, affecting overall sales.
Pacira BioSciences (Nasdaq: PCRX) announced an equity investment in GeneQuine Biotherapeutics to support gene therapy development for osteoarthritis. The initial investment is €2 million, with an additional €4 million contingent on achieving specific milestones related to its lead product, GQ-303. Up to €2.5 million will be in convertible notes. This investment aligns with Pacira's mission to advance non-opioid pain management solutions. GeneQuine’s gene therapy vectors aim to enhance joint function and reduce pain and inflammation.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net revenue of $429.6 million for 2020, a 2.0% increase from 2019. The fourth-quarter net product sales for EXPAREL reached $125.3 million, up from $116.9 million in 2019. Daily sales of EXPAREL were at 109% of the previous year's average for Q4 and 111% for December. Despite COVID-19 disruptions, EXPAREL's growth in elective and non-elective procedures highlights its role in non-opioid pain management. The complete financial results will be reported in Q1 2021.
PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 7:30 AM ET. Investors can access the live audio via the company's website. A replay will be available for two weeks post-event. Pacira is a leader in non-opioid pain management and regenerative health solutions, known for its long-acting local analgesic, EXPAREL®. The company acquired the handheld cryoanalgesia device, iovera⁰, in April 2019 to further its mission of reducing opioid reliance.
Pacira BioSciences (Nasdaq: PCRX) announced preliminary net product sales of $38.1 million for EXPAREL and $0.8 million for iovera° in November 2020, marking a continuation of year-over-year growth despite COVID-19 challenges. The company is optimistic about EXPAREL's increasing adoption in outpatient settings and diverse surgical procedures. However, 2020 sales were affected by pandemic-related elective surgery postponements. The firm will provide ongoing updates on sales for greater transparency as market dynamics evolve post-pandemic.
FAQ
What is the current stock price of Pacira BioSciences (PCRX)?
What is the market cap of Pacira BioSciences (PCRX)?
What is Pacira BioSciences, Inc. known for?
What are Pacira BioSciences' main products?
What is EXPAREL used for?
What recent financial milestone did Pacira achieve?
What is ZILRETTA?
How does ioveraº work?
What is the DepoFoam® delivery platform?
What are Pacira’s plans for 2024?
What is PCRX-201?
Where can I learn more about Pacira BioSciences?
